Estados Unidos aprueba el fármaco de Revolution que duplica la supervivencia en cáncer de páncreas
La FDA, el regulador de los fármacos estadounidense, aprueba la píldora Rasonque de Revolution Medicines, dentro de un proceso de revisión acelerada. Leer
The U.S. Food and Drug Administration (FDA) has approved Revolution Medicines' drug Rasonque to treat pancreatic cancer, significantly boosting patient survival rates. The once-daily pill received accelerated review and is specifically designated for metastatic pancreatic cancer in patients who have undergone prior treatment or are ineligible for combination chemotherapy.
Rasonque targets multiple forms of the RAS protein, which contributes to tumor growth in various pancreatic cancer types. Revolution announced the drug's availability in the U.S. at $39,800 for a 30-day supply, following a surge in demand after positive clinical trial results in April. The FDA expedited access to the drug under its compassionate use program, allowing seriously ill patients to receive experimental treatments before regulatory approval.
Investors have bet on Revolution, driven by optimism that Rasonque could become a key treatment option, pushing the company's shares up more than 170% this year. Analysts estimate the drug could generate $11.5 billion in global annual sales. The American Cancer Society predicts 67,350 new pancreatic cancer cases this year in the U.S., with around 10,338 new diagnoses in Spain annually, according to the Spanish Society of Medical Oncology.
Written by urgent.news from Expansion ES's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
